Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

185
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

215
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
215

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.

Journal of hepatology·2026
Same author

Fatty Pancreas and Risk of Type 2 Diabetes, Chronic Kidney Disease and Cardiovascular Events: Evidence From a Population-Based Cohort.

United European gastroenterology journal·2026
Same author

Reverse engineering of motor unit discharge in multiple sclerosis reveals heterogeneity of voluntary motor commands.

medRxiv : the preprint server for health sciences·2026
Same author

Dried Blood Spot: A Tool to Ensure Broad Access to Hepatitis D Screening, Diagnosis, and Treatment Monitoring.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

A novel methodological framework for the assessment of the neural control of the shoulder using high-density surface electromyography.

Methods (San Diego, Calif.)·2026
Same author

A randomized clinical trial to compare moxiFloxAcin veRsus aziTHromycin for the trEatment of MycoplaSma geniTalium: the FARTHEST Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Jan 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K

From Guidelines to Real-Time Conversation: Expert-Validated Retrieval-Augmented and Fine-Tuned GPT-4 for Hepatitis C

Mauro Giuffrè1,2, Nicola Pugliese3,4, Simone Kresevic5

  • 1Department of Internal Medicine (Section of Digestive Diseases), Yale School of Medicine, Yale University, New Haven, Connecticut, USA.

Liver International : Official Journal of the International Association for the Study of the Liver
|September 17, 2025
PubMed
Summary

Retrieval-augmented generation (RAG) and supervised fine-tuning (SFT) significantly improve large language models (LLMs) for Hepatitis C Virus (HCV) management. RAG-Top10 demonstrated superior accuracy and clarity in answering questions and recommending treatments.

Keywords:
ChatGPTgenerative artificial intelligencegenerative pretrained modelshepatitis C viruslarge language models

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.7K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.3K

Area of Science:

  • Artificial Intelligence in Medicine
  • Natural Language Processing for Healthcare
  • Chronic Disease Management Technologies

Background:

  • Large language models (LLMs) show potential for enhancing chronic disease management, specifically for Hepatitis C Virus (HCV) infection.
  • Evaluating AI techniques like retrieval-augmented generation (RAG) and supervised fine-tuning (SFT) is crucial for their clinical application.

Purpose of the Study:

  • To assess the impact of RAG and SFT on LLM performance in HCV management.
  • To evaluate LLM accuracy and clarity in open-ended question answering.
  • To determine the effectiveness of LLMs in recommending appropriate treatment regimens for HCV clinical scenarios.

Main Methods:

  • Utilized GPT-4 Turbo with baseline, RAG-Top1, RAG-Top10, and SFT configurations.
  • Employed the 2020 EASL HCV guidelines for external knowledge and fine-tuning.
  • Assessed LLM responses to 15 expert-vetted questions for accuracy and clarity.
  • Evaluated DAA regimen recommendations in 25 simulated clinical scenarios against expert consensus.

Main Results:

  • RAG-Top10 significantly improved accuracy (91.7%) and clarity (91.7%) over baseline (36.6% accuracy, 46.6% clarity) for question answering.
  • SFT also enhanced performance, achieving 71.7% accuracy and 88.3% clarity.
  • RAG-Top10 achieved the highest performance in recommending correct DAA regimens (76% vs. 24% for baseline).

Conclusions:

  • Both RAG and SFT substantially enhance LLM capabilities for guideline-driven HCV management.
  • RAG-Top10 offers the greatest benefits due to broader context retrieval.
  • Domain-specific alignment through SFT is valuable, highlighting the need for expert-informed evaluation frameworks for safe LLM integration.